Difference: VincentFischetti (4 vs. 5)

Revision 502 Apr 2009 - Main.SherryllJones

 
META TOPICPARENT name="TWikiUsers"

My Links

Personal Preferences

Uncomment preferences variables to activate them (remove the #-sign). Help and details on preferences variables are available in TWikiPreferences.

  • Show tool-tip topic info on mouse-over of WikiWord links, on or off:
    • #Set LINKTOOLTIPINFO = off
  • Horizontal size of text edit box:
    • #Set EDITBOXWIDTH = 70
  • Vertical size of text edit box:
    • #Set EDITBOXHEIGHT = 22
  • Style of text edit box. width: 99% for full window width (default), width: auto to disable.
    • #Set EDITBOXSTYLE = width: 99%
  • Write protect your home page: (set it to your WikiName)

Related Topics

Added:
>
>
Public Information on Grants associated with NYSBC_
 
Added:
>
>		Grant Number: 2R01AI011822-34A1Project Title: Properties of streptococcal M protein PI Information: Name Email Title FISCHETTI, VINCENT A. vaf@rockefeller.edu PROFESSOR
 
Added:
>
>		Abstract: DESCRIPTION (provided by applicant): Our main objective is to develop methods to protect against streptococcal infections in particular and gram-positive infections in general. Group A streptococcal-associated disease (pharyngitis, rheumatic fever, necrotizing fasciitis, impetigo, and scarlet fever, to name a few) affects millions of people, particularly children, worldwide. In developing countries, rheumatic heart disease is the major cause of heart damage in the school-age population. The severity of streptococcal diseases provides the impetus to develop novel methods to both prevent and treat these infections. Using a mucosal vaccine approach we have been successful in achieving cross-protection against heterologous streptococcal serotypes in a mouse model using the conserved region of the streptococcal M protein as the antigen. This approach circumvents the need to prepare type- specific antigens directed to the >120 streptococcal M serotypes. Furthermore, since the only reservoir for group A streptococci is the human pharynx, we have used a model system to successfully decolonized the oral cavity of mice of colonizing group A streptococci using a specific phage lytic enzyme. We hope to use this approach to reduce the bacterial burden in the human population and thus reduce disease. The experiments outlined in this proposal will expand these findings to develop both a new generation streptococcal vaccine and a prophylactic treatment to prevent streptococcal infections. In addition, during our studies, we identified a novel glycosylated enzyme in group A streptococci that is responsible for both attachment of surface proteins and cell wall assembly. This novel molecule is not ribosomally synthesized and as such we wish to determine its method of assembly. Since this glycoprotein is also found in other gram- positive bacteria (i.e., staphylococci and pneumococci) an understanding of its biosynthesis should offer novel targets for antibiotic development against these and perhaps other bacterial pathogens. The complete or partial M protein has not yet been crystallized. To better understand the details of the M protein structure and its multifunctional capacity, we will collaborate to solve the crystal structure of the biologically active N- and C-terminal halves of the molecule. Since many surface proteins on gram-positive bacteria are extended coiled-coil structures of modular design, structural data for the M molecule will allow for a better understanding of other surface proteins on gram-positives. In summary, our continued studies on gram-positive pathogenic bacteria over the >30 years of this grant has revealed new information regarding these pathogens enabling new strategies for their control; this application will continue in this direction.

Public Health Relevance: This Public Health Relevance is not available.

Thesaurus Terms: There are no thesaurus terms on file for this project.

Institution: ROCKEFELLER UNIVERSITY NEW YORK, NY 100656399 Fiscal Year: 2008 Department: BACTERIAL PATHOGENESIS & IMMUNOLOGY LAB Project Start: 01-APR-1997 Project End: 31-MAY-2012 ICD: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES IRG: BACP

 
META FORM name="Main.UserForm"
FORM FIELD FirstName FirstName? Vincent
FORM FIELD LastName LastName? Fischetti
FORM FIELD OrganisationName OrganisationName? Rockefeller University
FORM FIELD OrganisationURL OrganisationURL? http://www.rockefeller.edu/vaf
FORM FIELD Profession Profession Medical Research
FORM FIELD Country Country USA
FORM FIELD State State NY
FORM FIELD Address Address 1230 York Ave
FORM FIELD Location Location RockefellerUOffice
FORM FIELD Telephone Telephone 212-327-8166
FORM FIELD VoIP VoIP?
FORM FIELD InstantMessaging (IM) InstantMessagingIM?
FORM FIELD Email Email vaf@rockefeller.edu
FORM FIELD HomePage HomePage?
FORM FIELD Comment Comment
Added:
>
>
FORM FIELD Name Name
FORM FIELD Company Name CompanyName?
FORM FIELD Company URL CompanyURL?
 
META PREFERENCE name="VIEW_TEMPLATE" title="VIEW_TEMPLATE" type="Local" value="UserView"
View topic  |  History: r6 < r5 < r4 < r3  |  More topic actions...
 
Copyright © by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding this intranet, Send feedback